Department of Pharmaceutical Technology, Dr. Dayaram Patel Pharmacy College, Bardoli 394601, Gujarat, India.
Department of Pharmaceutical Technology, Shree S. K. Patel College of Pharmaceutical Education and Research, Ganpat University, Mehsana-384012, Gujarat, India.
Curr Pharm Biotechnol. 2024;25(15):1952-1968. doi: 10.2174/0113892010268824231122041237.
Biotech drugs, including proteins, hormones, enzymes, DNA/RNA therapies, and cell-based treatments, are gaining popularity due to their effectiveness. However, effective delivery systems are needed to overcome administration challenges. Lipid nanoparticles (LNPs) have emerged as promising carriers for various therapies. LNPs are biocompatible, less likely to cause adverse reactions, and can stabilize delicate biological drugs, enhancing their stability and solubility. Scalable and cost-effective manufacturing processes make LNPs suitable for largescale production. Despite recent research efforts, challenges in stability, toxicity, and regulatory concerns have limited the commercial availability of LNP-based products. This review explores the applications, administration routes, challenges, and future directions of LNPs in delivering biopharmaceuticals.
生物技术药物，包括蛋白质、激素、酶、DNA/RNA 疗法和基于细胞的治疗药物，由于其有效性而越来越受欢迎。然而，需要有效的给药系统来克服给药方面的挑战。脂质纳米粒（LNP）作为各种疗法的有前途的载体而出现。LNP 具有生物相容性，不太可能引起不良反应，并且可以稳定脆弱的生物药物，提高其稳定性和溶解度。规模化和具有成本效益的制造工艺使 LNP 适合大规模生产。尽管最近进行了研究，但在稳定性、毒性和监管方面的挑战限制了基于 LNP 的产品的商业可用性。本综述探讨了 LNP 在递送生物制药方面的应用、给药途径、挑战和未来方向。
